Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares

Sana Biotechnology, Inc.

Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.
Annual base salary of $515,000 with target bonus of 40% of base salary.
Granted option to purchase 900,000 shares (25% vest year 1, then monthly) and 200,000 RSUs (4-yr annual vest).
Piper previously CFO at Scorpion Therapeutics, Antares Therapeutics, and Prelude Therapeutics; over 25 years biopharma finance experience.
Company expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) in next 12-18 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.